{"url_path":"/sec/bpth/8-k/2026-07-16/item-7-01","section_key":"item-7-01","section_title":"Item 7.1 Regulation FD Disclosure**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1133818/0001663577-26-000218-index.html","accession_number":"0001663577-26-000218","cik":"0001133818","ticker":"BPTH","issuer_name":"BIO-PATH HOLDINGS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1133818/0001663577-26-000218-index.html","primary_entity_key":"0001133818","primary_entity_name":"BIO-PATH HOLDINGS, INC."},"word_count":87,"has_tables":true,"body_markdown":"**Item 7.1 Regulation FD Disclosure**\n\n** **\n\nWe are in the midst of a strategic turnaround\nwhich may include organically restarting Phase 2 drug trials, assessing the viability of Phase 1 drug trials, partnering, licensing, or\nselling our intellectual property, pivoting to blockchain technology to manage and finance our drug discovery trials, raising outside\ncapital, and/or managing our finances, performing strategic acquisitions and investments to generate growth outside of biotechnology,\nand improving our capital structure. There are no assurances that any or all of our efforts will be successful."}